Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06185400

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Disitamab Vedotin ERBB2 Gene Duplication ERBB2 Mutation-Related Tumors Non Small Cell Lung Cancer

Interventions Disitamab Vedotin pyrotinib third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)

Updated 3 times since 2024 Last updated: Dec 28, 2023 Started: Feb 1, 2024 Primary completion: Jul 1, 2025 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Disitamab Vedotin and ERBB2 Gene Duplication and is currently actively recruiting participants. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.